<DOC>
	<DOCNO>NCT00315861</DOCNO>
	<brief_summary>Currently , data exists regard safety tolerability combination regimen utilize weekly topotecan combination pemetrexed . Although drug associate myelosuppression , hop utilization weekly topotecan dose schedule allow drug easily combine . This phase I trial evaluate safety tolerability weekly topotecan combination pemetrexed patient advance solid tumor .</brief_summary>
	<brief_title>Topotecan Combination With Pemetrexed Patients With Advanced Malignancies</brief_title>
	<detailed_description>Three patient accrue 5 dose level . Dose escalation proceed none additional 3 patient experience DLT . The high dose level generates DLT 0/3 1/6 patient maximum tolerate dose ( MTD ) dose recommended subsequent study . A total 10 patient treat MTD assess toxicity dose regimen suitability use subsequent trial . Patients may continue receive treatment unacceptable toxicity disease progression encounter . Treatment cycle repeat every 21 day . The protocol also design enroll additional 10 patient maximum tolerate dose increase confidence safety suitability dose choose subsequent study . - Topotecan Day 1 8 - Pemetrexed Day 1</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically proven advanced solid tumor Measurable evaluable disease Age ≥ 18 year Karnofsky performance status ≥ 80 % ( ECOG 0 1 ) Adequate liver , bone marrow kidney function More 3 prior chemotherapy regimen metastatic set Prior treatment topotecan pemetrexed Clinically significant third space fluid present time treatment Unable interrupt aspirin , nonsteroidal antiinflammatory drug Inability take steroid premedications vitamin supplementation The presence active brain metastasis Prior radiotherapy within 4 week prior first day treatment Prior surgery within 3 week prior first day treatment Prior chemotherapy within 3 week prior first day treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>ovarian carcinoma</keyword>
	<keyword>endometrial carcinoma</keyword>
	<keyword>cervical carcinoma</keyword>
	<keyword>lung carcinoma</keyword>
</DOC>